ADMA Biologics Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ADMA Biologics de 32.5% y 11.4% respectivamente, mientras que el BPA crecerá en un 32.3% al año.

Información clave

32.5%

Tasa de crecimiento de los beneficios

32.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.1%
Tasa de crecimiento de los ingresos	11.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

Aug 22

ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

Aug 14

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:ADMA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	432	135	131	146	3
12/31/2025	390	114	120	125	4
12/31/2024	334	67	44	43	4
12/31/2023	258	-28	4	9	N/A
9/30/2023	234	-23	-23	-16	N/A
6/30/2023	208	-40	-51	-41	N/A
3/31/2023	182	-48	-61	-48	N/A
12/31/2022	154	-66	-73	-60	N/A
9/30/2022	130	-70	-99	-86	N/A
6/30/2022	110	-73	-99	-86	N/A
3/31/2022	94	-78	-119	-105	N/A
12/31/2021	81	-72	-126	-112	N/A
9/30/2021	69	-74	-125	-111	N/A
6/30/2021	58	-74	-135	-122	N/A
3/31/2021	48	-75	-124	-111	N/A
12/31/2020	42	-76	-115	-102	N/A
9/30/2020	40	-67	-100	-89	N/A
6/30/2020	37	-61	-99	-89	N/A
3/31/2020	36	-54	-92	-87	N/A
12/31/2019	29	-48	-80	-76	N/A
9/30/2019	21	-56	-78	-75	N/A
6/30/2019	18	-59	-66	-64	N/A
3/31/2019	16	-61	-62	-61	N/A
12/31/2018	17	-66	-65	-63	N/A
9/30/2018	18	-61	-61	-57	N/A
6/30/2018	18	-61	-58	-54	N/A
3/31/2018	17	-55	-52	-48	N/A
12/31/2017	16	-44	-40	-37	N/A
9/30/2017	14	-35	N/A	-28	N/A
6/30/2017	12	-24	N/A	-22	N/A
3/31/2017	11	-21	N/A	-18	N/A
12/31/2016	11	-20	N/A	-18	N/A
9/30/2016	10	-20	N/A	-19	N/A
6/30/2016	9	-20	N/A	-17	N/A
3/31/2016	8	-19	N/A	-16	N/A
12/31/2015	7	-18	N/A	-15	N/A
9/30/2015	6	-17	N/A	-14	N/A
6/30/2015	6	-15	N/A	-14	N/A
3/31/2015	6	-15	N/A	-14	N/A
12/31/2014	6	-17	N/A	-15	N/A
9/30/2014	5	-18	N/A	-15	N/A
6/30/2014	5	-17	N/A	-15	N/A
3/31/2014	4	-18	N/A	-13	N/A
12/31/2013	3	-16	N/A	-11	N/A
9/30/2013	3	-13	N/A	-10	N/A
6/30/2013	2	-14	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ADMA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que ADMA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ADMA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (11.4% al año) de ADMA crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.4% al año) de ADMA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ADMA se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ADMA Biologics Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

Price target increased by 15% to US$6.88

ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025

ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025

Price target increased by 20% to US$6.00

ADMA Biologics, Inc. Updates Earnings Guidance for the Full Year 2023, 2024 and 2025

Recent updates

ADMA Biologics, Inc., Annual General Meeting, Jun 04, 2024

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam

Full year 2023 earnings: EPS misses analyst expectations

ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025

ADMA Biologics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Price target increased by 15% to US$6.88

ADMA Biologics: On A Roll Entering 2024

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025

ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older

ADMA Biologics, Inc. Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Co-Founder & Vice Chairman of the Board recently bought US$482k worth of stock

Executive VP recently sold US$973k worth of stock

Co-Founder notifies of intention to sell stock

Price target increased by 20% to US$6.00

ADMA Biologics, Inc. Updates Earnings Guidance for the Full Year 2023, 2024 and 2025

ADMA Biologics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

ADMA Biologics, Inc Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Financial Guidance for the Year 2023 and 2024-2025

ADMA Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

ADMA Biologics, Inc. Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

Adma Biologics, Inc. Provides Earnings Guidance for the Full Year 2023

Price target increased to US$5.13

ADMA Biologics, Inc. Announces FDA Approval for Room Temperature Storage of Asceniv™ & Bivigam®

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $59.999997 million.

ADMA Biologics, Inc. Announces Revenue Guidance for the Quarter and Year Ending December 31, 2022

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased to US$5.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

No longer forecast to breakeven

ADMA Biologics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ADMA Biologics, Inc. Receives FDA Approval for Its Seventh Plasma Collection Center, Located in Greensboro, NC

No longer forecast to breakeven

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ADMA Biologics, Inc. Provides Earnings Guidance for the Fiscal Year 2022 and 2024

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

ADMA Biologics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

ADMA Biologics, Inc. Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ADMA Biologics, Inc. Provides Revenue Guidance for the Remainder of 2022

ADMA Biologics: A Path To Profits Looks Clear

ADMA Biologics, Inc. Revises Earnings Guidance for the Year 2022

ADMA Biologics, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$5.83

ADMA: Pertinent Updates

Consensus forecasts updated

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

ADMA Biologics, Inc. to Report Q4, 2021 Results on Mar 24, 2022

ADMA Biologics, Inc. Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

Price target increased to US$6.50

ADMA Biologics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021